LUDI Therapeutics is a biotech company in Monaco, founded in 2020, focused on treating sports injuries and muscle healing. The company prides itself on successfully merging the worlds of biotechnology and sports by specializing in regenerative medicine. With a team of experts in elite sports, sport medicine, drug discovery, and regenerative medicine, LUDI Therapeutics is dedicated to developing innovative drugs that aid in the healing process of physical injuries. Their flagship program involves improving the healing process for muscle injuries.
Notably, LUDI Therapeutics attracted a Seed Round investment at 25 May 2021 from Sport Horizon Holding. This funding has further empowered the company to advance its research and development efforts in the field of regenerative medicine, particularly in the context of sports-related injuries. As the company continues to make strides in its groundbreaking approach to treating sports-related injuries, it remains a key player in the biotechnology and health care industries. With its unique focus and strong investor backing, LUDI Therapeutics is poised to make a significant impact in the realm of sports medicine and regenerative healthcare.
